September, 2017

Opportunity Exists for Pharma to Assist IDNs in Managing Patient Population Across Conditions

Health systems fail to achieve a high level of success in managing patient populations across all conditions.

September, 2017

C-Suite Executives Identify the Majority of Biopharmaceutical Relationships

Market Access Customer Relationships—IDN Channel   |   Research Released September 2017

Health Strategies Group assigns company relationships with c-suite executives to one of the five following categories:

Definitions

C-Suite Executives Identify the Majority of Biopharmaceutical Relationships as Transactional or Collaborative

September, 2017

A Small Number of Medicaid MCOs and PBAs Control Most of the Pharmacy Benefit

The top eight MCOs now represent over half of all managed Medicaid.

September, 2017

Ten Medicare Plans Cover 81% of Medicare Part D Lives

United, Aetna, and Kaiser experienced increases of 10% each in total covered lives in 2017.

September, 2017

Leading Plans Continue to Grow

Seven plans currently insure over half of the U.S. insured population; the top three insurers cover 36% of the insured lives in the United States.

August, 2017

Assessing Your National Account Relationships

How does Aetna perceive its relationship with your company? How can you improve your relationship with Aetna?

August, 2017

Top Attributes Driving Asthma Access Decisions

Net pricing and outcomes data most drive health plan access decisions for branded asthma drugs; clinical data most drive medical group choices.

August, 2017

Commercial plans prioritize cost reduction

Biopharmaceutical companies can leverage the importance commercial plans place on clinical goals by offering compelling, clinically differentiating value propositions for their products in order to direct plans to shift their focus beyond unit product costs to total disease/care management

August, 2017

Payers Will Decrease Reliance on PBMs If They Fail To Improve their Services by Developing Specific Capabilities

The majority of health plans and employers anticipate accessing important services and capabilities through internal development or external contracting if PBM offerings remain unsatisfactory.

August, 2017

Prevalence of Base-Price Discount Contracts Diminishes as IDNs Increase Experimentation with Different Contracts

IDNs favor outcomes-based contracts for categories in which outcomes can be objectively measured. While outcomes-based contracts are still uncommon, IDNs most prefer them for antibiotics, COPD, hepatitis C, and multiple sclerosis agents.

Pages

Subscribe to RSS - blamb@healthstrategies.com's blog

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.